Back

Interventional patent foramen ovale closure or medical therapy only for the prevention of recurrent strokes: A meta analysis of available randomized trials

25 August 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 4 - Non-coronary cardiac interventions Patent Foramen Ovale (PFO) / Atrial Septal Defect (ASD) Closure ESC Premium Access ESC Congress 2018

About the speaker

Photo
Doctor Davor Vukadinovic

Saarland University Hospital, Homburg (Germany)

8 More presentations in this session

Presentation thumbnail
Interventional patent foramen ovale closure or medical therapy for cryptogenic ischemic stroke: an updated meta-analysis of randomized controlled trials
Doctor Y. Lin (Ibbenbueren, DE)
Abstract Slides
Presentation thumbnail
In-hospital results of 84 percutaneous pulmonary valve implantations
Doctor A. Fronczak (Warsaw, PL)
Abstract
Presentation thumbnail
Aortic root changes after device closure of interatrial communications
Associate Professor M. Abdelghani (Cairo, EG)
Abstract Slides
Presentation thumbnail
Multislice computed tomography SYNTAX score for coronary artery disease evaluation prior to transcatheter aortic valve implantation
Doctor G. Costa (Pisa, IT)
Abstract Slides
Presentation thumbnail
Advanced image processing with fusion and calcification enhancement in transcatheter aortic valve implantation: impact on radiation exposure
Mr P. Overtchouk (Bern, CH)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 4 - Non-coronary cardiac interventions

The Event

Event poster

ESC Congress 2018

25 August - 29 August 2018
You may be interested in
thumbnail
Congress Presentation
A reversible cause of heart failure?
thumbnail
Congress Presentation
Navigating anatomical barriers: successful amplatzer closure of a high-risk patent foramen ovale after failed noblestitch
thumbnail
Congress Presentation
Anatomical classification of patent foramen ovale before percutaneous closure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources